Tom Spurling – Executive Director – Nova Eye Medical (ASX:EYE) is introducing a comprehensive portfolio of novel glaucoma treatment options which span the entire disease process – enabling physicians to intervene earlier, and more often, in the treatment of glaucoma.
Copyright 2023 – Finance News Network
19 Sep 2019 - Recce Pharmaceuticals Limited (ASX:RCE) Executive Director, James Graham provides an update on the company's lead product RECCE 327, including its progress with manufacturing, securing patents and presenting to a global audience.
17 Feb 2023 - Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari discusses the company's upcoming plans to list on the NASDAQ and provides an update on the its clinical trials.
29 Jul 2022 - INOVIQ Limited (ASX:IIQ) CEO Dr Leearne Hinch discusses recent key announcements, including the appointment of a US sales team, the securing of a US patent, quarterly results, and the year ahead.
16 Sep 2022 - eCargo Holdings Limited (ASX:ECG) Group CEO Laurence Lun discusses highlights from the company's interim results, operations during lockdown and future milestones.
08 Jul 2021 - ImpediMed Limited (ASX:IPD) CEO and Managing Director Richard Carreon discusses the company's bioimpedance spectroscopy platform SOZO, which is particularly targeted at noninvasive clinical assessment and monitoring of fluid status and tissue composition in the treatment of secondary lymphoedema, heart failure and renal failure.
05 Mar 2024 - Chariot Corporation Limited (ASX:CC9) Managing Director Shanthar Pathmanathan discusses reasons behind the company's expansion of its Black Mountain holding.
27 May 2021 - Next Science Limited (ASX:NXS) Founder and Chief Technology Officer Dr Matthew Myntti talks about the problem of biofilms, Next Science's antimicrobial treatments and the company's recent FDA approval.
29 Mar 2021 - Telix Pharmaceuticals Limited (ASX:TLX) Chief Business Officer Dr David Cade talks about the company's clinical programs, including approvals, partnerships and significant value events anticipated in 2021.